Wireframe preview

Best viewed on desktop.

This is a wireframe for review, not the finished site. The responsive (mobile) treatment comes in the design and build phase. Open this page on a screen at least 1200 px wide to see the layout as intended.

← The GRA Portfolio

Inhibikase

Pharmaceuticals

Developer of preventative and curative treatments for infectious diseases that affect more than 100 million patients worldwide. Products under development include treatments for rare diseases, hepatitis B and C, biodefense, respiratory infectious disease and diarrhrea. Product pipeline anticipates FDA clinical trial clearance in 2013 for its treatment to treat the cause of progressive multifocal leukoencephalopathy (PML).